Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC6019-0001 · NNC6019

Other · developed by Novo Nordisk

Phase 3 Most advanced trial
NVO Developer
1 Registered trials

What is NNC6019-0001?

NNC6019-0001 is an agent administered intravenously. It is being studied in transthyretin amyloid cardiomyopathy (ATTR CM).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC6019
Drug type
Other
Therapy area
Cardiovascular
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07207811 Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) Recruiting NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

More from Novo Nordisk

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind NNC6019-0001

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.